Length of follow-up varied widely between the included studies. All values reported here were adjusted for publication bias where it was observed.
Vestibular schwannoma: There were 37 case series (3,677 patients). Rate of stabilised disease was 91.1% (95% CI 89.1 to 92.8). Rate of non-cranial nerve complications was 5.6% (95% CI 4.2 to 7.6). Overall rate of serviceable hearing preservation was 59.3% (95% CI 51.9 to 66.4). Rate of new facial palsy was 7.1% (95% CI 4.1 to 10.4). Rate of improvement in tinnitis was 17.1% (95% CI 10.8 to 26.0). Rate of surgical resection was 3.7% (95% CI 2.7 to 5.3).
Glioblastoma multiforme: There were nine case series, one case control study and one randomised controlled trial (456 patients). Median survival from diagnosis ranged from 13.5 to 26 months for stereotactic radiosurgery compared with 13 to 23 months for comparison groups. Overall complication rate was 11.4% (95% CI 5.1 to 23.6).
Meningioma: There were 15 case series (2,734 patients). Rate of stabilised disease was 89% (95% CI 86.4 to 92.3). Rate of complications was 7% (95% CI 5.3 to 9.3).
Intracranial metastatic disease: There were 25 case series and two randomised controlled trials (2,679 patients). Overall median survival from time of stereotactic radiosurgery was five to 14 months. One-year survival rates ranged from 15% to 54.9%. Local disease control rates range from 59.6% to 96.8%. Overall complication rate was 10% (95% CI 6.4 to 15.3).